Eastern Cooperative Oncology Group

描述（由申请人提供）：梅奥诊所已成为东方肿瘤合作组织（ECOG）成员37年。本申请通过U10机制申请资金，以继续作为西非经济共同体的主要机构成员。梅奥诊所的教师和附属机构参与了包括临床和转化研究在内的关键科学角色。梅奥诊所是nci指定的综合癌症中心，自1973年以来一直得到持续资助。历史上，梅奥诊所癌症中心（MCCC）的主要优势一直是高质量的临床研究、实践定义的临床试验、多学科转化研究和生物统计学。在2004年1月1日至2008年3月12日期间，4,114名患者被纳入主要机构、cccp和次要ccp的ECOG研究。与上一个资助周期的55篇论文和58篇摘要相比，梅奥或梅奥附属作者发表了98篇全文手稿和89篇摘要。主要成就包括以下几点。梅奥首席研究员撰写了两项新药试验，这些试验导致fda批准的适应症（用于弥漫性大b细胞淋巴瘤的利妥昔单抗（E4494 Dr. TM Habermann）和用于多发性骨髓瘤的沙利度胺（E1A04 Dr. SV Rajkumar））。高剂量地塞米松的血栓形成风险改变了骨髓瘤的治疗方法（E4A03 SV Rajkumar博士）。在白血病方面，细胞遗传学委员会主席GW Dewald博士报告说，复杂的核型导致急性淋巴细胞白血病预后差，治疗失败的风险增加。在多发性骨髓瘤中，Dr. R. Fonseca及其同事报道了t（11,14）和肿瘤抑制因子pl6甲基化的临床意义。具体目标是：1.)作为一个主要机构，通过CGOP项目和次要CCOP项目，促进ECOG研究的积累；2.)为ECOG提供临床科学领导和资源，与ECOG降低恶性肿瘤相关发病率和死亡率的使命相一致；3.)为恶性疾病的生物学知识的进步提供基础和转化的科学领导和资源，特别强调疾病导向的专业知识和/或梅奥诊所独特的项目，4.)在ECOG中提供行政角色，以支持集团的使命和目标。

DESCRIPTION (provided by applicant): The Mayo Clinic has been a member of the Eastern Cooperative Oncology Group (ECOG) for 37 years. This application is submitted to request funding via the U10 mechanism to continue as a main institution member of the ECOG. Mayo Clinic faculty and affiliated institutions have participated in key scientific roles including clinical and translational studies. The Mayo Clinic is an NCI-designated Comprehensive Cancer Center that has been continuously funded since 1973. Historically, the major strengths of the Mayo Clinic Cancer Center (MCCC) have been in high quality clinical research, practice-defining clinical trials, multidisciplinary translational studies, and biostatistics. Between 1/1/04 and 12/3/08, 4,114 patients were accrued to ECOG studies by the main institution, CGOPs, and secondary CCOPs. 98 full-length manuscripts were published with Mayo or Mayo affiliate authors and 89 abstracts were presented versus 55 papers and 58 abstracts in the previous grant cycle. Major accomplishments include the following. Mayo principal investigator authorship occurred on two trials with new agents that lead to FDA-approved indications (rituximab in diffuse large B-cell lymphoma (E4494 Dr. TM Habermann) and thalidomide in multiple myeloma (E1A04 Dr. SV Rajkumar). The thrombotic risks of high-dose dexamethasone changed the practice in myeloma (E4A03 Dr SV Rajkumar). In leukemia, Dr. GW Dewald as Chair of the Cytogenetics Committee, reported that a complex karyotype confers a poor prognosis with increased risk of treatment failure in acute lymphocytic leukemia. In multiple myeloma, new biologic insights were reported in the clinical implications of t(11,14) and tumor suppressor pl6 methylation by Dr. R. Fonseca and colleagues. The specific aims are 1.) to contribute to accrual to ECOG studies as a main institution, and through CGOP programs and secondary CCOP programs, 2.) to provide clinical scientific leadership and resources to the ECOG consistent with the ECOG mission of reducing malignancy-related morbidity and mortality, 3.) to provide basic and translational scientific leadership and resources for the advancement of knowledge of the biology of malignant diseases with particular emphasis on disease-oriented expertise and/or programs unique to the Mayo Clinic, and 4.) to provide an administrative role in ECOG to support the Group's mission and goals. RELEVANCE: Participation and contributions in this mechanism have lead to new therapeutic approaches that have changed the natural history of diffuse large B-cell lymphoma and multiple myeloma improving patient survival. Biologic observations are predicting outcomes and moving to new therapeutic approaches in patients with outcomes as predicted by their presenting biology.